散结镇痛胶囊联合阿奇霉素治疗慢性盆腔炎临床研究
|
摘要
目的探讨散结镇痛胶囊联合阿奇霉素治疗慢性盆腔炎的临床疗效。方法选取湖北省妇幼保健院2015年1月至2018年3月收治的慢性盆腔炎患者105例,按随机数字表法分为对照组(52例)和观察组(53例)。两组患者均口服阿奇霉素片,观察组患者加服散结镇痛胶囊,均连续服用7 d。结果观察组总有效率为96. 23%,明显高于对照组的82. 69%(P <0. 05);与治疗前比较,两组患者治疗后的丙二醛(MDA)、晚期氧化蛋白产物(AOPP)、肿瘤坏死因子-α(TNF-α)水平均显著下降(P <0. 05),且观察组显著低于对照组(P <0. 05);超氧化物歧化酶(SOD)、谷胱甘肽过氧化物酶(GSH-Px)、白细胞介素2(IL-2)、白细胞介素10(IL-10)水平均显著升高(P <0. 05),且观察组显著高于对照组(P <0. 05);观察组不良反应发生率为1. 89%,明显低于对照组的15. 38%(P <0. 05)。结论散结镇痛胶囊联合阿奇霉素治疗慢性盆腔炎,可减轻氧化应激和炎性应激反应,并可明显减少不良反应。
Objective To investigate the clinical efficacy of Sanjie Zhentong Capsules combined with azithromycin in the treatment of chronic pelvic inflammation. Methods Totally 105 patients with chronic pelvic inflammation admitted to Hubei Maternal and Child Health Hospital from January 2015 to March 2018 were selected and divided into the control group( 52 cases) and the observation group( 53 cases) according to the random number table method. The patients in the two groups took Azithromycin Tablets orally,while the patients in the observation group took Sanjie Zhentong Capsules on the basis of the control group. Both groups were treated continuously for 7 d. Results The total effective rate of the observation group was 96. 23%,which was significantly higher than 82. 69% of the control group( P < 0. 05). Compared with those before treatment,the levels of malondialdehyde( MDA),advanced oxidative protein product( AOPP) and tumor necrosis factor-α( TNF-α) in the two groups were significantly decreased after treatment( P < 0. 05),and those in the observation group were sinificantly lower than those in the control group( P < 0. 05). The levels of superoxide dismutase( SOD),glutathione peroxidase( GSH-Px),interleukin-2( IL-2),IL-10 in the two groups were significantly increased after treatment( P < 0. 05),and those in the observation group were significantly higher than those in the control group( P < 0. 05). The incidence of adverse reactions in the observation group was 1. 89%,which was significantly lower than 15. 38% in the control group( P < 0. 05).Conclusion Sanjie Zhentong Capsules combined with azithromycin in the treatment of chronic pelvic inflammation can alleviate oxidative stress and inflammatory emergency reaction,and also can significantly reduce adverse reactions.
Objective To investigate the clinical efficacy of Sanjie Zhentong Capsules combined with azithromycin in the treatment of chronic pelvic inflammation. Methods Totally 105 patients with chronic pelvic inflammation admitted to Hubei Maternal and Child Health Hospital from January 2015 to March 2018 were selected and divided into the control group( 52 cases) and the observation group( 53 cases) according to the random number table method. The patients in the two groups took Azithromycin Tablets orally,while the patients in the observation group took Sanjie Zhentong Capsules on the basis of the control group. Both groups were treated continuously for 7 d. Results The total effective rate of the observation group was 96. 23%,which was significantly higher than 82. 69% of the control group( P < 0. 05). Compared with those before treatment,the levels of malondialdehyde( MDA),advanced oxidative protein product( AOPP) and tumor necrosis factor-α( TNF-α) in the two groups were significantly decreased after treatment( P < 0. 05),and those in the observation group were sinificantly lower than those in the control group( P < 0. 05). The levels of superoxide dismutase( SOD),glutathione peroxidase( GSH-Px),interleukin-2( IL-2),IL-10 in the two groups were significantly increased after treatment( P < 0. 05),and those in the observation group were significantly higher than those in the control group( P < 0. 05). The incidence of adverse reactions in the observation group was 1. 89%,which was significantly lower than 15. 38% in the control group( P < 0. 05).Conclusion Sanjie Zhentong Capsules combined with azithromycin in the treatment of chronic pelvic inflammation can alleviate oxidative stress and inflammatory emergency reaction,and also can significantly reduce adverse reactions.
引文
[1]李维,邹亮,龚云,等.妇科千金片对阿奇霉素在慢性盆腔炎大鼠体内药物动力学的影响[J].中国中药杂志,2016,41(12):2339-2343.
[2]刘树金.2种中药保留灌肠方法对慢性盆腔炎疗效和生存质量的影响[J].中国药业,2015,24(4):91-92.
[3]何苗.散结镇痛胶囊联合复方大血藤灌肠剂治疗子宫内膜异位症的疗效分析[J].中国妇幼保健,2017,32(7):1431-1434.
[4]刘晓娟,范爱萍,薛凤霞.《2015年美国疾病控制和预防中心关于盆腔炎性疾病的诊治规范》解读[J].国际妇产科学杂志,2015,42(6):674-675.
[5]罗元恺.中医妇科学[M].第6版.北京:人民卫生出版社,1988:103-110.
[6]董莉,丁伟平,寿之炜,等.中西医结合治疗慢性盆腔炎临床疗效观察及安全性评价[J].中华中医药学刊,2014,32(9):2291-2293.
[7]陈泽,郑庆莉.探究莫西沙星联合桂枝茯苓胶囊对慢性盆腔炎患者血清IL-4、IL-10及TGF-β1的影响[J].中国生化药物杂志,2016,36(3):133-134.
[8]方海兰,符琴,王咸菊,等.妇乐颗粒联合左氧氟沙星和甲硝唑治疗急性盆腔炎的临床研究[J].现代药物与临床,2016,31(12):2025-2028.
[9]左翔.左氧氟沙星联合康妇消炎栓治疗慢性盆腔炎的临床效果分析[J].中国医药指南,2016,14(36):17-18.
[10]费春香,吴江平,吴瑛,等.宫瘤消胶囊联合散结镇痛胶囊对子宫腺肌病患者月经量、痛经的影响[J].现代中西医结合杂志,2015,24(35):3929-3931.
[11]ISMAIL M,MACKENZIE K,HASHIM H.Contemporary treatment options for chronic prostatitis/chronic pelvic pain syndrome[J].Drugs Today(Barc),2013,49(7):457-462.
[12]高巍,张莉,翟丽丽,等.米非司酮联合散结镇痛胶囊治疗子宫内膜异位症患者对性激素水平的影响[J].海南医学院学报,2016,22(22):2769-2771.
[2]刘树金.2种中药保留灌肠方法对慢性盆腔炎疗效和生存质量的影响[J].中国药业,2015,24(4):91-92.
[3]何苗.散结镇痛胶囊联合复方大血藤灌肠剂治疗子宫内膜异位症的疗效分析[J].中国妇幼保健,2017,32(7):1431-1434.
[4]刘晓娟,范爱萍,薛凤霞.《2015年美国疾病控制和预防中心关于盆腔炎性疾病的诊治规范》解读[J].国际妇产科学杂志,2015,42(6):674-675.
[5]罗元恺.中医妇科学[M].第6版.北京:人民卫生出版社,1988:103-110.
[6]董莉,丁伟平,寿之炜,等.中西医结合治疗慢性盆腔炎临床疗效观察及安全性评价[J].中华中医药学刊,2014,32(9):2291-2293.
[7]陈泽,郑庆莉.探究莫西沙星联合桂枝茯苓胶囊对慢性盆腔炎患者血清IL-4、IL-10及TGF-β1的影响[J].中国生化药物杂志,2016,36(3):133-134.
[8]方海兰,符琴,王咸菊,等.妇乐颗粒联合左氧氟沙星和甲硝唑治疗急性盆腔炎的临床研究[J].现代药物与临床,2016,31(12):2025-2028.
[9]左翔.左氧氟沙星联合康妇消炎栓治疗慢性盆腔炎的临床效果分析[J].中国医药指南,2016,14(36):17-18.
[10]费春香,吴江平,吴瑛,等.宫瘤消胶囊联合散结镇痛胶囊对子宫腺肌病患者月经量、痛经的影响[J].现代中西医结合杂志,2015,24(35):3929-3931.
[11]ISMAIL M,MACKENZIE K,HASHIM H.Contemporary treatment options for chronic prostatitis/chronic pelvic pain syndrome[J].Drugs Today(Barc),2013,49(7):457-462.
[12]高巍,张莉,翟丽丽,等.米非司酮联合散结镇痛胶囊治疗子宫内膜异位症患者对性激素水平的影响[J].海南医学院学报,2016,22(22):2769-2771.